Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

United States Lung Cancer Screening Rates Remain Low. s. in particular in the South.

2.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

3.

Simultaneously targeting lysosomal enzyme and KRAS-MAPK pathway eradicates pancreatic tumors in preclinical models

4.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

5.

A researcher has found that yoga exhibits the "most improvement" in helping long-term cancer survivors restore their brain health.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot